iScience, Volume 26

## **Supplemental information**

## **Cancer-specific glycosylation of CD13**

### impacts its detection and activity

# in preclinical cancer tissues

Francis M. Barnieh, Sebastian P. Galuska, Paul M. Loadman, Simon Ward, Robert A. Falconer, and Sherif F. El-Khamisy

#### Supplementary Information



**Fig. S1**. CD13 mRNA expression in CD13-CRISPR knockout THP-1 cells relative to expression in THP-1 wildtype cells



**Figure S2**. Quantified fold-change of CD13 protein expression in tumour xenograft relative to expression in their relative cell lines using different epitope-binding anti-CD13 antibodies. Mean fold-change in protein band intensity was measured using Image Lab Software 6.1 and normalised to a  $\beta$ -actin loading control.



**Figure S3**. Expression of neuraminidases and sialo-glycans in CDX and normal tissues (A) Differential expression of neuraminidases in tumour xenografts and normal tissues. (B) SNA and MAL-II lectin blot of tumour xenograft and normal tissues, to assess their binding affinity to  $\alpha 2,3$  and  $\alpha 2,6$  sialo-glycans respectively.



Figure S4. Coomassie staining of lectin affinity captured proteins in tumour xenograft and normal tissues.



**Figure S5**. LC-MS spectra of CD13 substrate metabolism in MCF-7 CDX homogenate in the presence specific glycosidases.

Lectin	Catalogue Number
Maackia Amurensis Lectin II (MAL II),	B-1265-1
Biotinylated	
Sambucus Nigra Lectin (SNA), Biotinylated	B-1305-2
Peanut Agglutinin (PNA), Biotinylated	B-1075-5
Soybean Agglutinin (SBA), Biotinylated	B-1015-5
Aleuria Aurantia Lectin (AAL), Biotinylated	B-1395-1
Ulex Europaeus Agglutinin I (UEA I),	B-1065-2
Biotinvlated	